Exclusive patent, know-how, process, technology, software and trade secret license to develop, package, label, commercialize, market, promote, import, distribute, offer, sell, use and sublicense products containing the antibody known as navenibart as an active pharmaceutical ingredient, to prevent hereditary angioedema (HAE) attacks in humans, which may be injected.